Gastroenterology Terapia 2020, 8 ( 391 ) : 4 - 13
Is targeted therapy for the treatment of irritable bowel syndrome possible?
Summary:
Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal disorder belonging to the group of disorders of intestinal-brain interaction. It is characterized by recurrent abdominal pain associated with defecation, changes in bowel rhythm and stool consistency.
The recommendations emphasize the fact that this disease is diagnosed on the basis of clinical symptoms, reliable medical history and physical examination. It is also recommended to diagnose IBS based on Roman Criteria IV.
Treatment of IBS should be determined on an individual basis and should depend on dominant symptoms, drug tolerance, and take into account potential etiological factors.
The disease is characterized by periods of exacerbation and remission, which induces patients to hold numerous consultations. Monitoring the response to treatment remains a challenge.
The recommendations emphasize the fact that this disease is diagnosed on the basis of clinical symptoms, reliable medical history and physical examination. It is also recommended to diagnose IBS based on Roman Criteria IV.
Treatment of IBS should be determined on an individual basis and should depend on dominant symptoms, drug tolerance, and take into account potential etiological factors.
The disease is characterized by periods of exacerbation and remission, which induces patients to hold numerous consultations. Monitoring the response to treatment remains a challenge.
Keywords: irritable bowel syndrome, diagnostics, targeted therapy, rifaximin, probiotics
If you would like to get the full article in Polish please contact our editorial office via email.
Add new comment